Minnesota Headlines

DelveInsight’s report titled “Myotonic Dystrophy Pipeline Insight 2023” offers extensive information on more than 25+ companies and over 28+ pipeline drugs in the field of Myotonic Dystrophy research. The Myotonic Dystrophy pipeline report encompasses detailed profiles of the pipeline drugs for Myotonic Dystrophy, including information on Myotonic Dystrophy clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

For the Myotonic Dystrophy emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Myotonic Dystrophy pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Myotonic Dystrophy clinical trial studies conducted for Myotonic Dystrophy, any NDA approvals obtained for Myotonic Dystrophy, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

To explore more information on the latest breakthroughs in the Myotonic Dystrophy Pipeline treatment landscape of the report, click here @ Myotonic Dystrophy Pipeline Outlook

Key Takeaways from the Myotonic Dystrophy Pipeline Report

• DelveInsight’s Myotonic Dystrophy Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies.
• The leading Myotonic Dystrophy Companies are working in the market include Lupin, AMO Pharma, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Nexien BioPharma, Locana Inc., Entrada Therapeutics, Arthex Biotech, NeuBase Therapeutics, NeuBase Therapeutics, Enzerna, Astellas Gene Therapies, Dyne Therapeutics, Pepgen Corporation, Sangamo Therapeutics, Syros Pharmaceuticals, and others.
• Emerging Myotonic Dystrophy Pipeline Therapies in the various stages of development include Mexiletine, Tideglusib, and others
• On May, 2023, AMO Pharma Limited announced a drug name of Tideglusib by phase 2. This is an open-label phase 2/3 study for children and adolescents with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or children and adolescents with either Congenital or Childhood Onset DM1 who are treatment naïve.
• On March, 2023, Lupin Ltd announced a drug name of Mexiletine by phase 3. This is an open-label, multi-centre, single arm, interventional study to describe the steady-state PK, safety, and efficacy of mexiletine in paediatric patients (6 to
• On February, 2023, AMO Pharma Limited announced a drug name of Tideglusib by phase 2. This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of patients (aged 6 to 16 years) diagnosed with Congenital Myotonic Dystrophy (Congenital DM1).

Myotonic Dystrophy Overview

Myotonic Dystrophy (DM) is considered a subgroup of myopathy and the most common type of muscular dystrophy that begins in adulthood. There are two major forms recognized based on clinical and molecular presentation: Myotonic dystrophy type I (DM1), known as Steinert disease, and myotonic dystrophy type II (DM2), or proximal myotonic myopathy which is a milder variety of DMI. These are progressive, multisystem genetic disorders.

For further information, refer to the detailed Myotonic Dystrophy Unmet Needs, Myotonic Dystrophy Market Drivers, and Market Barriers, click here for Myotonic Dystrophy Ongoing Clinical Trial Analysis

Myotonic Dystrophy Emerging Drugs Profile

• Mexiletine: Lupin
• AMO-02: AMO Pharma

Myotonic Dystrophy Pipeline Therapeutics Assessment

There are approx. 25+ key Myotonic dystrophy companies which are developing the therapies for Myotonic dystrophy. The Myotonic Dystrophy companies which have their Myotonic dystrophy drug candidates in the most advanced stage, i.e. Phase III include, Lupin.

Request a sample and discover the recent advances in Myotonic Dystrophy Ongoing Clinical Trial Analysis and Medications, click here @ Myotonic Dystrophy Treatment Landscape

Myotonic Dystrophy Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Myotonic Dystrophy Therapeutics Market include-

Lupin, AMO Pharma, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Nexien BioPharma, Locana Inc., Entrada Therapeutics, Arthex Biotech, NeuBase Therapeutics, NeuBase Therapeutics, Enzerna, Astellas Gene Therapies, Dyne Therapeutics, Pepgen Corporation, Sangamo Therapeutics, Syros Pharmaceuticals, and others.

Dive deep into rich insights for drugs for Myotonic Dystrophy Pipeline, click here @ Myotonic Dystrophy Unmet Needs and Analyst Views

Scope of the Myotonic Dystrophy Pipeline Report

• Coverage- Global
• Myotonic Dystrophy Companies- Lupin, AMO Pharma, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Nexien BioPharma, Locana Inc., Entrada Therapeutics, Arthex Biotech, NeuBase Therapeutics, NeuBase Therapeutics, Enzerna, Astellas Gene Therapies, Dyne Therapeutics, Pepgen Corporation, Sangamo Therapeutics, Syros Pharmaceuticals, and others.
• Myotonic Dystrophy Therapies- Mexiletine, Tideglusib, and others
• Myotonic Dystrophy Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Myotonic Dystrophy Mergers and acquisitions, Myotonic Dystrophy Licensing Activities @ Myotonic Dystrophy Emerging Drugs, and Recent Trends

Table of Content

1. Introduction
2. Myotonic Dystrophy Executive Summary
3. Myotonic dystrophy Overview
4. Myotonic dystrophy Pipeline Therapeutics
5. Myotonic dystrophy Therapeutic Assessment
6. Myotonic dystrophy (DM) – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mexiletine: Lupin
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase II)
11. Pitolisant: Harmony Biosciences
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DYNE-101: DYNE Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ENTR-701: Entrda Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Myotonic dystrophy Products
20. Myotonic dystrophy Key Companies
21. Myotonic dystrophy Key Products
22. Myotonic dystrophy Unmet Needs
23. Myotonic dystrophy Market Drivers
24. Myotonic dystrophy Market Barriers
25. Myotonic dystrophy Future Perspectives and Conclusion
26. Myotonic dystrophy Analyst Views
27. Myotonic dystrophy Companies
28. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/out-licensing-opportunity